کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8453299 | 1547877 | 2018 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Patients with secondary acute myeloid leukemia (sAML) have poor outcomes, with CR/CRi rates of 25-35% with standard 7â¯+â¯3 induction chemotherapy, while single center non-comparative analyses suggest promising outcomes with FLAG. We conducted a single-center, retrospective cohort study assessing outcomes in treatment-naïve patients with sAML treated with fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor (FLAG, nâ¯=â¯40) compared with 7â¯+â¯3 (nâ¯=â¯66). Median patient age was 63 years (range: 27-82) in the FLAG group and 60 years (range: 21-76) in the 7â¯+â¯3 group (Pâ¯=â¯0.968). Patients treated with FLAG achieved higher overall response rates (CRâ¯+â¯CRiâ¯+â¯MLFS) compared to 7â¯+â¯3 (70% vs. 48%, Pâ¯=â¯0.043). FLAG was well tolerated, with only one induction death (30-day mortality rate, 3% vs. 8%, Pâ¯=â¯0.405) and no cases of cerebellar toxicity. Duration of neutropenia was significantly shorter with FLAG (median 16 vs. 23â¯days, Pâ¯<â¯0.001). Half of the FLAG-treated patients proceeded to consolidative therapy compared with only 27% of those who received 7â¯+â¯3 (Pâ¯=â¯0.022). Overall survival was comparable between groups (8.5 mos, FLAG vs. 9.1 mos, 7â¯+â¯3; Pâ¯=â¯0.798). Thus, FLAG may represent a low-cost treatment strategy in sAML that produces higher response rates and promising survival outcomes with minimal treatment-related toxicity. Further studies are required to prospectively compare FLAG to the newly FDA-approved CPX-351 in sAML.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 70, July 2018, Pages 91-96
Journal: Leukemia Research - Volume 70, July 2018, Pages 91-96
نویسندگان
Vera Vulaj, Anthony J. Perissinotti, James R. Uebel, Victoria R. Nachar, Gianni B. Scappaticci, Ashley Crouch, Dale L. Bixby, Patrick W. Burke, Ivan Maillard, Moshe Talpaz, Bernard L. Marini,